# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 6, "Lancet", "", "<http://ctro/data#Publication_45906> <http://ctro/data#hasJournal> \"Lancet\"."
1, PublicationYear, 9, 13, "2013", "", "<http://ctro/data#Publication_45906> <http://ctro/data#hasPublicationYear> \"2013\"."
9, Title, 118, 322, "Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add - on or lone therapy ( INTERVAL ) : a 24 week , randomised , double - blind , placebo - controlled study .", "", "<http://ctro/data#Publication_45906> <http://ctro/data#hasTitle> \"Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add - on or lone therapy ( INTERVAL ) : a 24 week , randomised , double - blind , placebo - controlled study .\"."
82, Precondition, 155, 236, "elderly patients with type 2 diabetes using vildagliptin add - on or lone therapy", "", "<http://ctro/data#Population_45929> <http://ctro/data#hasPrecondition> \"elderly patients with type 2 diabetes using vildagliptin add - on or lone therapy\"."
3, Type2Diabetes, 177, 192, "type 2 diabetes", "", "<http://ctro/data#ClinicalTrial_45913> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
2, Vildagliptin, 199, 211, "vildagliptin", "", 
4, Duration, 254, 261, "24 week", "", "<http://ctro/data#ClinicalTrial_45913> <http://ctro/data#hasCTduration> \"24 week\"."
5, Randomized, 264, 274, "randomised", "", "<http://ctro/data#ClinicalTrial_45913> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
6, DoubleBlind, 277, 291, "double - blind", "", "<http://ctro/data#ClinicalTrial_45913> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
7, Placebo, 294, 301, "placebo", "", 
10, Author, 323, 332, "Strain WD", "", "<http://ctro/data#Publication_45906> <http://ctro/data#hasAuthor> \"Strain WD\"."
11, Author, 341, 354, "Lukashevich V", "", "<http://ctro/data#Publication_45906> <http://ctro/data#hasAuthor> \"Lukashevich V\"."
12, Author, 363, 371, "Kothny W", "", "<http://ctro/data#Publication_45906> <http://ctro/data#hasAuthor> \"Kothny W\"."
13, Author, 380, 393, "Hoellinger MJ", "", "<http://ctro/data#Publication_45906> <http://ctro/data#hasAuthor> \"Hoellinger MJ\"."
14, Author, 402, 416, "Pald á nius PM", "", "<http://ctro/data#Publication_45906> <http://ctro/data#hasAuthor> \"Pald á nius PM\"."
15, UK, 539, 541, "UK", "", 
96, USA, 662, 665, "USA", "", 
97, Switzerland, 703, 714, "Switzerland", "", 
98, Precondition, 912, 949, "elderly patients with type 2 diabetes", "", 
16, Type2Diabetes, 934, 949, "type 2 diabetes", "", 
22, ObjectiveDescription, 974, 1146, "We aimed to assess the feasibility of setting and achieving individualised targets over 24 weeks along with conventional HbA1c reduction using vildagliptin versus placebo .", "", "<http://ctro/data#ClinicalTrial_45913> <http://ctro/data#hasObjectiveDescription> \"We aimed to assess the feasibility of setting and achieving individualised targets over 24 weeks along with conventional HbA1c reduction using vildagliptin versus placebo .\"."
18, Duration, 1062, 1070, "24 weeks", "", 
19, HbA1c, 1095, 1100, "HbA1c", "", 
20, Vildagliptin, 1117, 1129, "vildagliptin", "", 
21, Placebo, 1137, 1144, "placebo", "", 
23, Multicenter, 1165, 1178, "multinational", "", "<http://ctro/data#ClinicalTrial_45913> <http://ctro/data#hasCTDesign> <http://ctro/data#Multicenter>."
24, DoubleBlind, 1181, 1195, "double - blind", "", 
25, Duration, 1198, 1205, "24 week", "", 
113, HbA1c, 1268, 1296, "glycosylated haemoglobin A1c", "", 
27, HbA1c, 1299, 1304, "HbA1c", "", 
28, Percentage, 1315, 1316, "%", "", 
116, Percentage, 1329, 1330, "%", "", 
29, Type2Diabetes, 1347, 1362, "type 2 diabetes", "", 
30, MinAge, 1368, 1370, "70", "", "<http://ctro/data#Population_45929> <http://ctro/data#hasMinAge> \"70\"."
112, Multicenter, 1391, 1412, "45 outpatient centres", "", 
117, TimePoint, 1498, 1506, "baseline", "", 
32, HbA1c, 1507, 1512, "HbA1c", "", 
119, Randomized, 1586, 1594, "randomly", "", 
33, AllocationRatio, 1615, 1620, "1 : 1", "", "<http://ctro/data#AllocationRatio_45917> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#AllocationRatio>. <http://ctro/data#ClinicalTrial_45913> <http://ctro/data#hasAllocationRatio> <http://ctro/data#AllocationRatio_45917>."
34, Vildagliptin, 1626, 1638, "vildagliptin", "", "<http://ctro/data#Medication_45967> <http://ctro/data#hasDrug> <http://ctro/data#Vildagliptin>."
35, DoseValue, 1641, 1643, "50", "", "<http://ctro/data#Medication_45967> <http://ctro/data#hasDoseValue> \"50\"."
36, mg, 1644, 1646, "mg", "", "<http://ctro/data#Medication_45967> <http://ctro/data#hasDoseUnit> <http://ctro/data#mg>."
123, Frequency, 1647, 1666, "once or twice daily", "", "<http://ctro/data#Intervention_45955> <http://ctro/data#hasFrequency> \"once or twice daily\"."
38, Placebo, 1685, 1692, "placebo", "", "<http://ctro/data#Medication_45974> <http://ctro/data#hasDrug> <http://ctro/data#Placebo>."
39, HbA1c_target, 1790, 1802, "HbA1c target", "", 
40, HbA1c, 1807, 1812, "HbA1c", "", 
41, TimePoint, 1828, 1836, "baseline", "", 
42, TimePoint, 1840, 1849, "study end", "", 
43, Randomized, 2087, 2095, "randomly", "", 
133, NumberPatientsArm, 2105, 2108, "139", "", "<http://ctro/data#Arm_45937> <http://ctro/data#hasNumberPatientsArm> \"139\". <http://ctro/data#Arm_45946> <http://ctro/data#hasNumberPatientsArm> \"139\"."
45, Vildagliptin, 2130, 2142, "vildagliptin", "", 
46, Placebo, 2147, 2154, "placebo", "", 
47, NumberAffected, 2164, 2166, "37", "", "<http://ctro/data#Outcome_46021> <http://ctro/data#hasNumberAffected> \"37\"."
48, PercentageAffected, 2169, 2171, "27", "", "<http://ctro/data#Outcome_46021> <http://ctro/data#hasPercentageAffected> \"27\"."
93017, FinalNumPatientsArm, 2179, 2182, "137", "", "<http://ctro/data#Arm_45946> <http://ctro/data#hasFinalNumPatientsArm> \"137\"."
50, Placebo, 2199, 2206, "placebo", "", 
66189, HbA1c_target, 2243, 2250, "targets", "", "<http://ctro/data#Endpoint_45989> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c_target>."
51, NumberAffected, 2311, 2313, "72", "", "<http://ctro/data#Outcome_45994> <http://ctro/data#hasNumberAffected> \"72\"."
52, PercentageAffected, 2316, 2322, "52 · 6", "", "<http://ctro/data#Outcome_45994> <http://ctro/data#hasPercentageAffected> \"52 · 6\"."
93018, FinalNumPatientsArm, 2330, 2333, "137", "", "<http://ctro/data#Arm_45937> <http://ctro/data#hasFinalNumPatientsArm> \"137\"."
66197, HbA1c_target, 2358, 2364, "target", "", 
54, Vildagliptin, 2372, 2384, "vildagliptin", "", 
56, ConfIntervalDiff, 2431, 2449, "CI 1 · 81 - 5 · 52", "", "<http://ctro/data#DiffBetweenGroups_46048> <http://ctro/data#hasConfIntervalDiff> \"CI 1 · 81 - 5 · 52\"."
55, PvalueDiff, 2452, 2464, "p < 0 · 0001", "", "<http://ctro/data#DiffBetweenGroups_46048> <http://ctro/data#hasPvalueDiff> \"p < 0 · 0001\"."
57, Reduction, 2523, 2528, "0 · 9", "", "<http://ctro/data#Outcome_46062> <http://ctro/data#hasChangeValue> \"0 · 9\"."
58, Percentage, 2529, 2530, "%", "", 
59, HbA1c, 2544, 2549, "HbA1c", "", "<http://ctro/data#Endpoint_46057> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
146, TimePoint, 2557, 2565, "baseline", "", 
60, BaseLineValue, 2569, 2574, "7 · 9", "", "<http://ctro/data#Outcome_46062> <http://ctro/data#hasBaselineValue> \"7 · 9\"."
61, Percentage, 2575, 2576, "%", "", "<http://ctro/data#Endpoint_46057> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
62, Vildagliptin, 2582, 2594, "vildagliptin", "", 
63, DiffGroupAbsValue, 2631, 2638, "- 0 · 6", "", "<http://ctro/data#DiffBetweenGroups_46116> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 · 6\"."
64, Percentage, 2639, 2640, "%", "", 
65, ConfIntervalDiff, 2643, 2675, "98 · 8 % CI - 0 · 81 to - 0 · 33", "", "<http://ctro/data#DiffBetweenGroups_46116> <http://ctro/data#hasConfIntervalDiff> \"98 · 8 % CI - 0 · 81 to - 0 · 33\"."
66, PvalueDiff, 2678, 2690, "p < 0 · 0001", "", "<http://ctro/data#DiffBetweenGroups_46116> <http://ctro/data#hasPvalueDiff> \"p < 0 · 0001\"."
67, Vildagliptin, 2750, 2762, "vildagliptin", "", 
68, Placebo, 2767, 2774, "placebo", "", 
70, ObservedResult, 2789, 2802, "low incidence", "", 
69, Hypoglycemia, 2806, 2819, "hypoglycaemia", "", 
74, ConclusionComment, 2878, 3028, "This study is the first to introduce and show the feasibility of using individualised HbA1c targets as an endpoint in any type 2 diabetes population .", "", "<http://ctro/data#ClinicalTrial_45913> <http://ctro/data#hasConclusionComment> \"This study is the first to introduce and show the feasibility of using individualised HbA1c targets as an endpoint in any type 2 diabetes population .\"."
160, HbA1c_target, 2964, 2977, "HbA1c targets", "", 
73, Type2Diabetes, 3000, 3015, "type 2 diabetes", "", 
78, ConclusionComment, 3029, 3176, "Individualised glycaemic target levels are achievable with vildagliptin without any tolerability issues in the elderly type 2 diabetes population .", "", "<http://ctro/data#ClinicalTrial_45913> <http://ctro/data#hasConclusionComment> \"Individualised glycaemic target levels are achievable with vildagliptin without any tolerability issues in the elderly type 2 diabetes population .\"."
75, Vildagliptin, 3088, 3100, "vildagliptin", "", 
76, Type2Diabetes, 3148, 3163, "type 2 diabetes", "", 
79, PMID, 3317, 3325, "23706759", "", "<http://ctro/data#Publication_45906> <http://ctro/data#hasPMID> \"23706759\"."
